Evofem Biosciences, Inc. (EVFM)
| Previous Close | 0.0092 |
| Open | 0.0098 |
| Bid | 0.0100 x 1100 |
| Ask | 0.0110 x 1800 |
| Day's Range | 0.0098 - 0.0115 |
| 52 Week Range | 0.0060 - 0.2260 |
| Volume | |
| Avg. Volume | 1,163,562 |
| Market Cap | 1.104M |
| Beta (5Y Monthly) | -0.69 |
| PE Ratio (TTM) | 0.00 |
| EPS (TTM) | 6.5800 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
MOUNTAIN VIEW, Calif. & SAN DIEGO, October 08, 2024--Aditxt, Inc. ("Aditxt" ) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and Evofem Biosciences, Inc. ("Evofem") (OTCQB: EVFM), a pioneer in women's health, today announced the completion of the Third Parent Equity Investment under the Amended and Restated Merger Agreement, as amended (the "Agreement"). This investment further strengthens the strategic and collaborative relationship between the tw
- Business Wire
Aditxt Delivers Shareholder Update and 2024 Year-End Plan
MOUNTAIN VIEW, Calif., October 03, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today provided an update on its plans for 2024 year-end.
- Business Wire
Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
MOUNTAIN VIEW, Calif., September 24, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating promising health innovations, today announced that its acquisition target, Evofem Biosciences, Inc. ("Evofem") (OTCQB: EVFM), today filed a preliminary proxy to seek stockholder approval of transactions contemplated under the Amended and Restated Merger Agreement dated as of July 12, 2024 (the "Merger Agreement"), with Aditxt and Adifem, Inc., a who
